21 / 56
Adapted from Rodon J, et al.
Nat Rev Clin Oncol
. 2013;10(3):143-153 and Fruman DA, Rommel C.
Nat Rev Drug Discov
. 2014;13(2):140-156.
LY294002
Buparlisib
(BKM120)
PWT-458
Pilarlisib
ZSTK474
GSK615/
GSK1059615
CH5132799
Pictilisib
Copanlisib
Wortmannin
PI-103
XL765/SAR254409
GDC-0980
GSK1059615
PKI-587/ PF-05212384
PF-04691502
CAL-101
Alpelisib (BYL719
)
INK1117
AS-252424
GSK2636771
TGX-221
VQD-002 (API-2)/Triciribine
Perifosine (KRX-0401)
Catalytic
GDC-0068
GSK690693
Allosteric
MK-2206
Allosteric/Rapalogues
TORC1
Sirolimus (rapamycin)
Temsirolimus (CCI-779)
Everolimus (RAD001)
Ridaforolimus (AP-23573)
Catalytic
TORC1/2
AZD-8055
OSI-027
INK-128
PP-242
CC-223
Isoform-specific
PI3Ki
Pan-PI3Ki
PI3K/mTORi
mTORi
AKTi
PI3K-AKT-
mTOR
Pathway
21
Agents Inhibiting the PI3K-AKT-mTOR Pathway